Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief Scientific Officer, and President of R&D

  Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President,
  Chief Scientific Officer, and President of R&D

Business Wire

CAMBRIDGE, Mass. -- February 11, 2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the promotion of
Mark Currie, Ph.D. to senior vice president, chief scientific officer (CSO),
and president of research and development (R&D).

Mark Currie, Ph.D., senior vice president, CSO, and president of R&D of
Ironwood Pharmaceuticals, In ...

Mark Currie, Ph.D., senior vice president, CSO, and president of R&D of
Ironwood Pharmaceuticals, Inc. (Photo: Business Wire)

“Mark’s outstanding contributions to Ironwood, including his expertise,
leadership and superb judgment, are invaluable as we move our R&D efforts
forward, growing our active pipeline and expanding our development efforts
globally on behalf of our shareholders and the patients we aim to serve,” said
Peter Hecht, chief executive officer of Ironwood. “Mark’s pioneering academic
research on the guanylate cyclase-C (GC-C) pathway, including his discovery of
the natural hormones that activate GC-C, established the foundation for the
discovery of linaclotide by Ironwood scientists, and he has led every aspect
of linaclotide’s development and regulatory review, resulting in LINZESS™
(linaclotide) being the first and only GC‐C agonist approved in the U.S.,
Constella^® (linaclotide) being the first therapy approved for patients with
IBS-C in Europe, and linaclotide development programs advancing in Japan and
China.”

Dr. Currie has led the company’s R&D efforts since he joined Ironwood in 2002
and previously served as senior vice president, R&D and CSO at Ironwood. Prior
to that, he directed cardiovascular and central nervous system disease
research as vice president of discovery research at Sepracor Inc. Previously,
Dr. Currie initiated, built, and led discovery pharmacology and also served as
director of arthritis and inflammation at Monsanto Company. Dr. Currie earned
a B.S. in biology from the University of South Alabama and holds a Ph.D. in
cell biology from the Bowman-Gray School of Medicine of Wake Forest
University.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical
company dedicated to the art and science of great drugmaking. Ironwood is
located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130211005762/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50559652&lang=en

Contact:

Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa Buffington, 617-374-5103
Vice President, Corporate Communications
lbuffington@ironwoodpharma.com
or
Investor Relations
Meredith Kaya, 617-374-5082
Associate Director, Investor Relations
mkaya@ironwoodpharma.com